Related content

New genetic associations in thiopurine-related bone marrow toxicity among inflammatory bowel disease patients

By Zabala William   Cruz Raquel   Barreiro-de Acosta Manuel   Chaparro María   Panes Julián   Echarri Ana   Esteve Maria   Carpio Daniel   Andreu Montserrat   García-Planella Esther   Domenech Eugeni   Carracedo Angel   Gisbert Javier P   Barros Francisco  

Pharmacogenomics, Vol. 14, Iss. 6, 2013-04 ,pp. : 631-640

Future Medicine

Access to resources Recommend Favorite

The interaction of 6-mercaptopurine (6-MP) and methotrexate (MTX) - an update with focus on mechanisms involved in toxicity

By Giverhaug T.   Loennechen T.   Aarbakke J.  

General Pharmacology, Vol. 33, Iss. 4, 1999-10 ,pp. : 341-346

Elsevier

Access to resources Recommend Favorite

Genetic and Environmental Influences on Therapeutic and Toxicity Outcomes: Studies with CYP2A6

By  

Current Clinical Pharmacology, Vol. 1, Iss. 3, 2006-09 ,pp. : 291-309

Bentham Science Publishers

Access to resources Recommend Favorite

Characterization of the CYP2D6 gene locus and metabolic activity in Indo- and Afro-Trinidadians: discovery of novel allelic variants

By Montané Jaime Lazara Karelia   Lalla Anthony   Steimer Werner   Gaedigk Andrea  

Pharmacogenomics, Vol. 14, Iss. 3, 2013-02 ,pp. : 261-276

Future Medicine

Access to resources Recommend Favorite

Mercaptopurine "should remain the standard thiopurine in continuing therapy of childhood lymphoblastic leukaemia"

By  

Inpharma, Vol. 1, Iss. 1560, 2006-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite